FILIP1L Inhibits Ovarian Cancer Metastasis through Inhibition of WNT Signaling
Abstract
Ovarian cancer is the deadliest gynecologic malignancy and the fifth leading cause of death from cancer in women. Ovarian cancer kills ~15,000 women in the United States alone every year. This is because it is a highly aggressive type of cancer that is often diagnosed only when it has spread throughout the peritoneal cavity. The overall survival rate in these patients has been improved by recent advances in chemotherapy, but still remains poor. Thus, there is a need for new therapeutic options, especially targeting ovarian cancer spread. We have identified novel tumor suppressor protein, FILIP1L, that inhibits ovarian cancer spread, and we now propose to study its mechanism of action. Understanding the mechanism through which FILIP1L exerts its effect will allow for the development of novel therapeutic approaches in ovarian cancer. Completion of the proposed studies will provide immediate and important insights into the role of FILIP1L in regulating the spread of ovarian cancer. As a long-range outcome, compounds mimicking FILIP1L activity or specifically inducing its expression could therefore be developed as novel therapies for ovarian cancer. As an increasing number of women are members of all branches of our military, cancers that affect women present a risk to our national defense. As ovarian cancer spread is a major source of patient mortality, the outcome of the proposed research will likely benefit active duty Service members, Veterans, and their dependents.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Apr 04, 2016
- Source ID
- W81XWH1510369
Entities
People
- Steven Libutti
Organizations
- Albert Einstein College of Medicine
- United States Army